GNH USA

Europe — EMA

Irsamla (Vortioxetine Hydrobromide)

GNH USA supplies Irsamla (Vortioxetine Hydrobromide), a serotonin modulator and stimulator for major depressive disorder. Request a quote for global supply.

Vortioxetine Hydrobromide

Request sourcing

1
Pack/s

What is Vortioxetine Hydrobromide?

Vortioxetine Hydrobromide, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional outcomes.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for regulated medicines. Customers benefit from comprehensive regulatory support and timely delivery across multiple regions.

What is Vortioxetine Hydrobromide used for?

Vortioxetine Hydrobromide (Irsamla) is used in the management of depressive disorders by modulating serotonergic neurotransmission.

- Major depressive disorder: reduces depressive symptoms and improves functional recovery.

What are the side effects of Vortioxetine Hydrobromide?

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth

Serious or Rare Side Effects: - Serotonin syndrome - Suicidal thoughts or behavior - Severe hyponatremia - Allergic reactions such as rash or angioedema

What precautions apply to Vortioxetine Hydrobromide?

Before initiating therapy, assess psychiatric history and evaluate risk of suicidal ideation.

- Monitor for serotonin syndrome: watch for agitation, hyperreflexia, fever. - Avoid abrupt discontinuation: taper under medical supervision. - Use caution in hepatic impairment: consider dose adjustment. - Store at ambient temperature: keep in original container, protect from moisture and light.

What does Vortioxetine Hydrobromide interact with?

Vortioxetine may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Linezolid: avoid due to MAO inhibition.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase vortioxetine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic efficacy. - Anticoagulants (e.g., warfarin): monitor INR and bleeding risk.

Frequently asked questions

What is Irsamla used for?+
Irsamla contains vortioxetine hydrobromide and is prescribed for the treatment of major depressive disorder in adult patients. It helps alleviate depressive symptoms and can improve overall functional outcomes by enhancing serotonergic activity in the brain.
How does Vortioxetine work?+
Vortioxetine acts as a serotonin modulator and stimulator. It blocks several serotonin receptors, stimulates the 5‑HT1A receptor, and inhibits the serotonin transporter, resulting in increased serotonin availability and balanced neurotransmission across multiple pathways.
What is the usual dose of Irsamla?+
The appropriate dose of Irsamla is determined by the prescribing healthcare professional based on the individual’s clinical condition, response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Irsamla safe during pregnancy or breastfeeding?+
Safety data for vortioxetine in pregnancy and lactation are limited. The prescriber will weigh potential benefits against possible risks to the fetus or infant before deciding to use Irsamla in these populations.
How do I order Irsamla from GNH USA?+
To request Irsamla, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Irsamla compare with other antidepressants?+
Irsamla (vortioxetine) differs from traditional SSRIs by also modulating multiple serotonin receptors, which may offer benefits for cognition and fewer sexual side effects. However, individual response varies, and the choice of antidepressant should be guided by the prescriber based on patient profile and tolerability.
How should Irsamla be stored and handled?+
Store Irsamla at ambient temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.
How is Irsamla administered?+
Irsamla is taken orally as a tablet, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare professional.
What are the most serious risks associated with Irsamla?+
Serious risks include serotonin syndrome, emergence of suicidal thoughts or behaviors, severe hyponatremia, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience any of these symptoms.
Who should not use Irsamla?+
Irsamla should not be used by individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with known hypersensitivity to vortioxetine or any tablet excipients. Caution is also advised in patients with severe hepatic impairment or a history of serotonin syndrome.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Vortioxetine Hydrobromide
Route
Oral Use
Manufacturer
Egis Pharmaceuticals Plc
Origin
EU

Related products

Brintellix

Brintellix

Vortioxetine Hydrobromide

H. Lundbeck A/S
EU
Brintellix

Brintellix

Vortioxetine Hydrobromide

H. Lundbeck A/S
EU
Brintellix

Brintellix

Vortioxetine Hydrobromide

H. Lundbeck A/S
EU
Irsamla

Irsamla

Vortioxetine Hydrobromide

Egis Pharmaceuticals Plc
EU